LA JOLLA, CA – June 6, 2016 – Synthetic Genomics, Inc. (SGI) announced today that Oliver Fetzer, Ph.D., MBA, Chief Executive Officer of Synthetic Genomics, Inc., will provide a corporate overview and presentation at the Jefferies 2016 Healthcare Conference on Friday, June 10, 2016 at 8:30am ET (5:30am PT) in New York, NY.
La Jolla, CA, May 3, 2016—Synthetic Genomics, Inc. (SGI), a leader in the field of synthetic biology, announced today that Anthony Artuso has joined its executive team as Chief Business Officer. Anthony is an accomplished executive and entrepreneur with over 20 years of broad domestic and international experience in biotech, clean energy, finance, public policy, and sustainable development.
(LA JOLLA, CA)—March 24, 2016—Researchers from Synthetic Genomics Inc. (SGI) and the J. Craig Venter Institute (JCVI) announced today the design and construction of the first minimal synthetic bacterial cell, JCVI-syn3.0. Using the first synthetic cell, Mycoplasma mycoides JCVI-syn1.0 (created by this same team in 2010), JCVI-syn3.0 was developed through a design, build, and test process using genes from JCVI-syn1.0.
La Jolla, CA, March 3, 2016 – Synthetic Genomics, Inc. (SGI), a leader in the field of synthetic biology, announced today that Robert H. (Rob) Cutler is joining its executive team as General Counsel and Corporate Secretary. Rob has 20 years of corporate legal, intellectual property licensing, regulatory compliance, business development and mergers and acquisitions experience, most of which has been spent in the biotech industry in private and public companies and earlier in his career at leading law firms.
LA JOLLA, CA – January 13, 2016 – SGI-DNA, a Synthetic Genomics, Inc. (SGI) company, announced today that the world’s first DNA printer, the BioXp™ 3200 System, has reached another milestone with the release of the BioXp™ cloning module. The addition of the cloning module to the instrument repertoire further solidifies SGI-DNA as an industry leader at the forefront of synthetic biology innovations and solutions.
LA JOLLA, CA – January 6, 2016 – Synthetic Genomics, Inc. (SGI) announced today that Oliver Fetzer, Ph.D., MBA, chief executive officer of Synthetic Genomics, Inc., will provide a corporate overview and presentation at the J.P. Morgan 34th Annual Healthcare Conference on Wednesday, January 13, 2016 at 1:00 p.m. ET (10:00 a.m. PT) in San Francisco, California.
(LA JOLLA, CA) December 15, 2015- SGI-DNA, a Synthetic Genomics, Inc. (SGI) company, has launched a suite of Cell Engineering Services for generation of custom mammalian cell lines for research use. Cell lines developed using this service are appropriate for the expression of novel proteins as well as a variety of functional studies, including cell-based assays for compound screening.
(LA JOLLA, CA) December 3, 2015 – SGI-DNA Inc., a Synthetic Genomics Inc. company, announces the launch of beta-testing of the BioXp™ 3200 System Cloning Module, equipping researchers with the ability to synthesize and clone their DNA with an overnight instrument run. The benchtop BioXp™ System, the world’s first DNA printer, is a genomic workstation that generates high-quality DNA from custom designed reagents.
(LA JOLLA, CA) September 1, 2015, 2015- SGI-DNA, a Synthetic Genomics, Inc. company announces the launch of the Gibson Assembly® Site-Directed Mutagenesis Kit which allows researchers to efficiently and accurately perform site-directed mutagenesis on DNA fragments. This kit is the third in SGI-DNA’s Gibson Assembly® portfolio, which empowers life science researchers to substantially increase their ability to build genes, edit them, and study their functions using nucleotide insertions, substitutions, or deletions.
